
Shanghai Yizhong Pharmaceutical Co., Ltd.
SSE:688091.SS
46.25 (CNY) • At close June 11, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|---|
Assets: | ||||||||
Current Assets: | ||||||||
Cash & Cash Equivalents
| 644.407 | 914.763 | 710.381 | 110.431 | 0.191 | 0.154 | 3.167 | 2.714 |
Short Term Investments
| 0 | 325.418 | 338.897 | 832.648 | 40.658 | 130.379 | 160.221 | 99.61 |
Cash and Short Term Investments
| 644.407 | 1,240.182 | 1,049.278 | 943.078 | 40.85 | 130.533 | 3.167 | 2.714 |
Net Receivables
| 54.451 | 143.192 | 51.389 | 4.105 | 0 | 0 | 0.243 | 0 |
Inventory
| 45.17 | 28.406 | 17.061 | 11.781 | 1.477 | 2.73 | 2.285 | 0.284 |
Other Current Assets
| 32.179 | 1.906 | 81.983 | 24.536 | 5.4 | 4.779 | 44.477 | 99.61 |
Total Current Assets
| 776.207 | 1,413.244 | 1,199.711 | 993.551 | 57.727 | 138.042 | 166.163 | 103.32 |
Non-Current Assets: | ||||||||
Property, Plant & Equipment, Net
| 149.279 | 121.651 | 121.452 | 83.949 | 87.815 | 88.182 | 47.078 | 50.548 |
Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets
| 8.362 | 8.578 | 8.794 | 9.011 | 9.227 | 9.443 | 9.66 | 9.876 |
Goodwill and Intangible Assets
| 8.362 | 8.578 | 8.794 | 9.011 | 9.227 | 9.443 | 9.66 | 9.876 |
Long Term Investments
| 0 | 21.009 | 20.319 | 105.822 | 103.481 | 40 | 0 | 42.826 |
Tax Assets
| 7.62 | 5.645 | 1.842 | 6.07 | -103.481 | -40 | 0 | -42.826 |
Other Non-Current Assets
| 506.525 | 3.233 | 2.475 | 2.159 | 104.041 | 41.95 | 6.428 | 49.999 |
Total Non-Current Assets
| 671.786 | 160.116 | 154.883 | 207.011 | 201.083 | 139.575 | 63.165 | 110.422 |
Total Assets
| 1,447.993 | 1,573.359 | 1,354.594 | 1,200.562 | 258.81 | 277.617 | 229.328 | 213.743 |
Liabilities & Equity: | ||||||||
Current Liabilities: | ||||||||
Account Payables
| 27.696 | 37.695 | 21.534 | 1.116 | 2.198 | 1.908 | 7.624 | 9.355 |
Short Term Debt
| 0 | 44.028 | 0 | 16.75 | 3.25 | 0 | 0 | 0 |
Tax Payables
| 1.266 | 1.223 | 3.502 | 0.369 | 0.294 | 0.367 | 0.248 | 0.151 |
Deferred Revenue
| 0 | 0 | 0.122 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities
| 10.485 | 21.038 | 4.828 | 2.869 | 5.769 | 5.359 | 3.816 | 0.891 |
Total Current Liabilities
| 39.446 | 103.984 | 29.864 | 21.104 | 11.511 | 7.634 | 11.688 | 10.397 |
Non-Current Liabilities: | ||||||||
Long Term Debt
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue Non-Current
| 1.029 | 1.47 | 2.287 | 3.133 | 3.792 | 4.63 | 5.461 | 5.778 |
Deferred Tax Liabilities Non-Current
| 2.497 | 3.069 | 3.264 | 0.785 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities
| 0 | 0 | 2.287 | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Liabilities
| 3.526 | 4.539 | 5.551 | 3.918 | 3.792 | 4.63 | 5.461 | 5.778 |
Total Liabilities
| 42.972 | 108.523 | 35.415 | 25.022 | 15.304 | 12.264 | 17.149 | 16.175 |
Equity: | ||||||||
Preferred Stock
| 0 | 0 | 0 | 26.561 | 0 | 0 | 0 | 0 |
Common Stock
| 206.589 | 158.277 | 143.888 | 105.8 | 79.35 | 79.35 | 70.45 | 68.75 |
Retained Earnings
| 164.012 | 206.861 | 104.647 | -26.561 | -22.564 | -353.869 | -39.853 | -27.264 |
Accumulated Other Comprehensive Income/Loss
| 0 | 55.875 | 1,070.643 | -26.561 | 186.72 | 539.873 | 181.582 | -0 |
Other Total Stockholders Equity
| 1,034.419 | 1,043.824 | 1,070.643 | 1,122.862 | 186.72 | 539.873 | 181.582 | 156.082 |
Total Shareholders Equity
| 1,405.021 | 1,464.837 | 1,319.178 | 1,175.54 | 243.506 | 265.353 | 212.179 | 197.568 |
Total Equity
| 1,405.021 | 1,464.837 | 1,319.178 | 1,175.54 | 243.506 | 265.353 | 212.179 | 197.568 |
Total Liabilities & Shareholders Equity
| 1,447.993 | 1,573.359 | 1,354.594 | 1,200.562 | 258.81 | 277.617 | 229.328 | 213.743 |